Global POC Diagnostics Market 2023-2029

April 2023 | 76 pages | ID: G69965BAAF97EN
Gen Consulting Company

Abstracts

POC (Point-of-Care) diagnostics is essential for the rapid detection of analytes near to the patient, which facilitates better disease diagnosis, monitoring, and management. It enables quick medical decisions, as the diseases can be diagnosed at a very early stage, leading to improved health outcomes for patients by enabling the early start of treatment. POC diagnostics can be performed in a variety of settings, including hospitals, clinics, doctors' offices, and even in the patient's home. According to the latest estimates, the global POC diagnostics market is set to achieve an incremental growth of USD 21.3 billion, accelerating at a CAGR of almost 9.2% during the forecast period 2023-2029. The POC diagnostics market is a rapidly growing segment of the healthcare industry. The market is driven by several factors, including the increasing prevalence of infectious diseases, the growing demand for rapid and accurate diagnostic testing, and the need for cost-effective healthcare solutions.The POC diagnostics market is a rapidly growing segment of the healthcare industry. The market is driven by several factors, including the increasing prevalence of infectious diseases, the growing demand for rapid and accurate diagnostic testing, and the need for cost-effective healthcare solutions.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global POC diagnostics market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type, product, end user, and region. The global market for POC diagnostics can be segmented by type: alcohol and drug abuse, blood gas electrolyte and metabolite (BGEM), cardiac markers, cholesterol, glucose monitoring, hemoglobin/hemostasis, infectious diseases, pregnancy and fertility, urine chemistry, others. The glucose monitoring segment was the largest contributor to the global POC diagnostics market in 2022. POC diagnostics market is further segmented by product: hardware, software. According to the research, the hardware segment had the largest share in the global POC diagnostics market. Based on end user, the POC diagnostics market is segmented into: hospitals and critical care centers, home care settings. The home care settings segment held the largest revenue share in 2022. On the basis of region, the POC diagnostics market also can be divided into: Asia-Pacific, Europe, North America, Rest of the World (RoW). Globally, North America made up the largest share of the POC diagnostics market.

Market Segmentation

By type: alcohol and drug abuse, blood gas electrolyte and metabolite (BGEM), cardiac markers, cholesterol, glucose monitoring, hemoglobin/hemostasis, infectious diseases, pregnancy and fertility, urine chemistry, others

By product: hardware, software

By end user: hospitals and critical care centers, home care settings

By region: Asia-Pacific, Europe, North America, Rest of the World (RoW)

The report also provides analysis of the key companies of the industry and their detailed company profiles including Abaxis, Inc., Abbott Laboratories, Becton, Dickinson, and Co., Chembio Diagnostics, Inc., Danaher Corporation, EKF Diagnostics Holdings plc, F. Hoffmann-La Roche AG, Koninklijke Philips N.V., Medtronic plc, Mindray Medical International Limited, OraSure Technologies, Inc., Quidel Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Werfen GmbH, Wipro Limited, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report

• To analyze and forecast the market size of the global POC diagnostics market.
• To classify and forecast the global POC diagnostics market based on type, product, end user, region.
• To identify drivers and challenges for the global POC diagnostics market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global POC diagnostics market.
• To identify and analyze the profile of leading players operating in the global POC diagnostics market.

Why Choose This Report

• Gain a reliable outlook of the global POC diagnostics market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY TYPE

Alcohol and drug abuse
Blood gas electrolyte and metabolite (BGEM)
Cardiac markers
Cholesterol
Glucose monitoring
Hemoglobin/hemostasis
Infectious diseases
Pregnancy and fertility
Urine chemistry
Others

PART 6. MARKET BREAKDOWN BY PRODUCT

Hardware
Software

PART 7. MARKET BREAKDOWN BY END USER

Hospitals and critical care centers
Home care settings

PART 8. MARKET BREAKDOWN BY REGION

Asia-Pacific
Europe
North America
Rest of the World (RoW)

PART 9. KEY COMPANIES

Abaxis, Inc.
Abbott Laboratories
Becton, Dickinson, and Co.
Chembio Diagnostics, Inc.
Danaher Corporation
EKF Diagnostics Holdings plc
F. Hoffmann-La Roche AG
Koninklijke Philips N.V.
Medtronic plc
Mindray Medical International Limited
OraSure Technologies, Inc.
Quidel Corporation
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Werfen GmbH
Wipro Limited
DISCLAIMER